Apogee Therapeutics
Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immune (I&I) diseases with high unmet need.
Apogee is seeking to reshape the current standard of care for inflammatory and immune diseases because we believe people living with these diseases deserve the best possible treatment.
Our pipeline of differentiated antibody therapeutics targets well-established biological drivers and development pathways, with an initial focus on making impactful advancements in the treatment of atopic dermatitis and chronic obstructive pulmonary disease.
AWARDS
221 Crescent St
Waltham MA US
Waltham MA US
NEWS
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
Banking on its lead antibody APG777 for atopic dermatitis, Apogee Therapeutics is filing an initial public offering for an as-yet-undisclosed value.
JOBS
IN THE PRESS